Saturday 24 May 2025
|
08.00-09.00 |
Registration |
|
|
|
Electrochemotherapy in Veterinary Oncology: Mechanisms, Applications, and Emerging Therapies |
|
|
09.00-09.45 |
Electrochemotherapy in Human Oncology: From cutaneous primary and metastatic tumors to emerging applications in solid tumors |
Victor Farricha |
|
09.45-10.30 |
Electrochemotherapy and Immunotherapy: Mechanisms, Immunogenic Potential, and Emerging Combinations in Human and Veterinary Oncology |
Maja Cemazar |
|
10.30-11.00 |
Coffee break |
|
|
11.00-11.45 |
Electrochemotherapy in Veterinary Oncology: Practical Applications and Treatment Optimization |
Natasa Tozon |
|
11.45-12.30 |
Electroporation-Based Therapies in non-cutaneous tumours |
Matias Tellado |
|
12.30-13.00 |
Panel discussion |
Speaker Panel |
|
13.00-14.30 |
Lunch boxes will be provided |
|
|
|
General abstracts |
|
|
14.30-14.42 |
Anti-PD1 and Intratumoral GD2-directed IL2 Immunocytokine-Augmented Radiation-Induced In Situ Vaccination Combination Immunotherapy in Companion Dogs with Malignant Melanoma |
David Vail |
| 14.42-14.54 |
Evaluating the impact of elective nodal irradiation for dogs with oral malignant melanoma undergoing hypofractionated radiotherapy |
Patricia Gualtier |
| 14.54-15.06 |
Pharmacokinetics and Safety of Lysine-Specific Histone Demethylase-1 Inhibitor SP-2577 for Feline Oral Squamous Cell Carcinoma |
Jenna Burton |
| 15.06-15.18 |
Evaluation of a therapeutic vaccine against the tumor vascular marker versican in dogs with invasive urothelial cell carcinoma |
Lobke van Bergen |
| 15.18-15.30 |
Early detection of cancer using circulating tumor DNA in liquid biopsies: a first step to improve clinical care of Histiocytic Sarcoma through the follow-up of 30 Bernese Mountain Dogs |
Benoit Hedant |
|
15.30-16.00 |
Coffee break |
|
|
16.00-16.30 |
Sponsored talk by DeepScan
DeepScan CFD test for cancer treatment monitoring |
Dr. Katja Kivinen |
|
|
General abstracts |
|
|
16.30-16.42 |
Characterization of somatic mutations in lymphomas of Bernese Mountain dogs |
Valentina Granziera |
| 16.42-16.54 |
Survival outcomes of dogs diagnosed with urethral carcinoma treated with high-dose-rate iridium-192 brachytherapy and NSAIDs, NSAIDs alone or no treatment |
Jean-Baptiste Eon |
| 16.54-17.06 |
Staging Findings in Feline Radiotherapy Candidates: Incidence and Impact on Treatment Decisions |
Ian Lee |
| 17.06-17.18 |
Reirradiation of recurrent canine intracranial tumors |
Maximilian Körner |
| 17.18-17.30 |
IL-12/IL-23 as Serum Biomarkers to Measure Response and Prognosis in Canine Lymphoma |
Felicia Westling |
|
20.00 |
Gala Dinner |
|
